Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
Add more filters

Publication year range
1.
Toxicol Appl Pharmacol ; 466: 116489, 2023 05 01.
Article in English | MEDLINE | ID: mdl-36963521

ABSTRACT

In extrahepatic cholestasis, the molecular mechanisms of liver damage due to bile acid accumulation remain elusive. In this study, the activation of glutamatergic receptors was hypothesized to be responsible for bile acid-induced oxidative stress and liver damage. Recent evidence showed that lithium, as an N-methyl-d-aspartate receptor (NMDAR) GluN2B subunit inhibitor, may act on the glutamate/NMDAR signaling axis. Guinea pigs were assigned to four groups, as sham laparotomy (SL), bile duct ligated (BDL), lithium-treated SL (SL + Li) and lithium-treated BDL (BDL + Li) groups. Cholestasis-induced liver injury was evaluated by aspartate aminotransferase (AST), alanine transaminase (ALT), interleukin-6 (IL-6), tissue malondialdehyde (MDA), copper­zinc superoxide dismutase and reduced glutathione levels. The liability of glutamate/NMDAR signaling axis was clarified by glutamate levels in both plasma and liver samples, with the production of nitric oxide (NO), as well as with the serum calcium concentrations. Blood glucose, glucagon, insulin levels and glucose consumption rates, in addition to tissue glycogen were measured to evaluate the liver glucose-glycogen metabolism. A high liver damage index (AST/ALT) was calculated in BDL animals in comparison to SL group. In the BDL animals, lithium reduced plasma NO and glutamate in addition to tissue glutamate concentrations, while serum calcium increased. The antioxidant capacities and liver glycogen contents significantly increased, whereas blood glucose levels unchanged and tissue MDA levels decreased 3-fold in lithium-treated cholestatic animals. It was concluded that lithium largely protects the cholestatic hepatocyte from bile acid-mediated damage by blocking the NMDAR-GluN2B subunit.


Subject(s)
Cholestasis, Extrahepatic , Cholestasis , Liver Diseases , Animals , Guinea Pigs , Bile Acids and Salts/metabolism , Bile Ducts/metabolism , Blood Glucose/metabolism , Calcium/metabolism , Cholestasis/metabolism , Cholestasis, Extrahepatic/metabolism , Glutamates/metabolism , Ligation , Lithium/therapeutic use , Lithium Compounds/metabolism , Liver/metabolism , Liver Diseases/drug therapy , Liver Diseases/metabolism , Liver Glycogen/metabolism , Oxidative Stress
2.
Biol Reprod ; 107(4): 1059-1071, 2022 10 11.
Article in English | MEDLINE | ID: mdl-35871551

ABSTRACT

In mammals, dormant primordial follicles represent the ovarian reserve throughout reproductive life. In vitro activation of dormant primordial follicles has been used to treat patients with premature ovarian insufficiency (POI). However, there remains a lack of effective strategies to stimulate follicle activation in vivo. In this study, we used an in vitro ovarian culture system and intraperitoneal injection to study the effect of lithium treatment on primordial follicle activation. Lithium increased the number of growing follicles in cultured mouse ovaries and promoted pre-granulosa cell proliferation. Furthermore, lithium significantly increased the levels of phosphorylated protein kinase B (Akt) and the number of oocytes with forkhead Box O3a (FOXO3a) nuclear export. Inhibition of the phosphatidylinositol 3 kinase (PI3K)/Akt pathway by LY294002 reversed lithium-promoted mouse primordial follicle activation. These results suggest that lithium promotes mouse primordial follicle activation by the PI3K/Akt signaling. Lithium also promoted primordial follicle activation and increased the levels of p-Akt in mouse ovaries in vivo and in human ovarian tissue cultured in vitro. Taken together, lithium promotes primordial follicle activation in mice and humans by the PI3K/Akt signaling. Lithium might be a potential oral drug for treating infertility in POI patients with residual dormant primordial follicles.


Subject(s)
Primary Ovarian Insufficiency , Proto-Oncogene Proteins c-akt , Animals , Female , Humans , Lithium/metabolism , Lithium/pharmacology , Lithium Compounds/metabolism , Lithium Compounds/pharmacology , Mammals/metabolism , Mice , Oocytes/metabolism , Ovarian Follicle/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism
4.
Aging Clin Exp Res ; 27(3): 255-63, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25409859

ABSTRACT

Lithium modulates signals impacting on the cytoskeleton, a dynamic system contributing to neural plasticity at multiple levels. In this study, SH-SY5Y human neuronal cells were cultured in the absence (C) or in presence (Li) of a 0.5 mM Li2CO3 (i.e. 1 mM lithium ion) for 25-50 weeks. We investigated the effect of this treatment on (1) morphological changes of cells observed using Hemalun eosin staining assay, (2) cytoskeletal changes by indirect immunofluorescence (IIF) staining of microtubules (α-tubulin) and heavy neurofilaments subunits (NF-H) and by measuring the expression rate changes of genes coding for receptor for activated C kinase (RACK1), casein kinase2 (CK2) and thymosine beta-10 using cDNA arrays technology, (3) cell adhesion properties by IIF staining of ß-catenin protein. Besides, we have tried to understand the molecular mechanism of lithium action that triggers changes in cytoskeleton and neurites outgrowth. Thus, we examined the effect of this treatment on glycogen synthase kinase 3 (GSK3) expression and activity using western blotting of GSK3 and phosphorylated ß-catenin, a downstream GSK3 target protein. Our results showed that lithium treatment reduces axon length, increases axonal spreading, enhances neurites growth and neurites branching with an increase of growth cone size. Moreover, genes coding for CK2 and thymosine beta-10 were significantly up-regulated, however, that coding for RACK1 was down-regulated. The most interesting result in this work is that mechanism underlying lithium action was not related to the inhibition of GSK3 activity. In fact, neither expression rate nor activity of this protein was changed.


Subject(s)
Cytoskeleton , Glycogen Synthase Kinase 3/metabolism , Lithium Compounds , Nerve Degeneration , Neuronal Plasticity/drug effects , Cells, Cultured , Cytoskeleton/drug effects , Cytoskeleton/metabolism , Glycogen Synthase/metabolism , Glycogen Synthase Kinase 3 beta , Humans , Lithium Compounds/metabolism , Lithium Compounds/pharmacology , Nerve Degeneration/drug therapy , Nerve Degeneration/metabolism , Neurites/metabolism , Neurogenesis/drug effects , Neuroprotective Agents/metabolism , Neuroprotective Agents/pharmacology , Treatment Outcome
5.
Acta Odontol Scand ; 70(2): 114-21, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21780966

ABSTRACT

OBJECTIVES: To examine potential correlations between streptococcal biofilm formation and lactate production in streptococcal biofilms formed on the surface of dental materials with different surface characteristics. MATERIALS AND METHODS: Samples of a glass-ionomer cement (Ketac Molar) and a ceramic (Empress 2) were incubated with whole saliva and suspensions of Streptococcus mutans ATCC 25175 or Streptococcus sobrinus ATCC 33478 for initiating single-species biofilm formation for either 4 or 24 h. The relative amount of adherent, viable cells was determined using a Resazurin and a MTT assay. Metabolic activity was assessed by quantifying lactate production with a modification of the commercial Clinpro Cario L-Pop kit. RESULTS: Both assays identified similar S. sobrinus biofilm formation on the two substrata; for S. mutans, the MTT test showed significantly fewer streptococci on the glass-ionomer cement than on the ceramic. Concerning metabolic activity, for S. sobrinus, significantly higher lactate production was observed for biofilms formed on the glass-ionomer cement in comparison to the ceramic, whereas similar values were identified for S. mutans. CONCLUSIONS: Within the limitations of the study, the results suggest that the pure amount of adherent streptococci does not a priori indicate the metabolic activity of the cariogenic bacteria organized in the respective biofilm. Thus, comparisons between the relative amount of adherent streptococci and their metabolic activity may allow for an improved understanding of the effect of dental material surfaces on the formation and metabolic activity of streptococcal biofilms.


Subject(s)
Biofilms/growth & development , Dental Porcelain , Glass Ionomer Cements , Streptococcus mutans/metabolism , Streptococcus sobrinus/metabolism , Analysis of Variance , Bacterial Adhesion , Colony Count, Microbial , Female , Glass Ionomer Cements/metabolism , Glycolysis , Humans , Lactic Acid/metabolism , Lithium Compounds/metabolism , Saliva/microbiology , Statistics, Nonparametric , Surface Properties , Young Adult
6.
Medicina (B Aires) ; 72(2): 171-5, 2012.
Article in Spanish | MEDLINE | ID: mdl-22522861

ABSTRACT

For more than 40 years lithium has been used to treat bipolar disorder and recent trials suggest a potential efficacy also in the treatment of the amnestic mild cognitive impairment. Lithium is filtered by the glomerulus and 65% - 75% of the filtered amount is reabsorbed along the proximal tubule and in the thick ascending limb of Henle's loop by the Na+, K+, 2Cl- transporter and via paracellular. A small fraction of lithium is reabsorbed in the collecting duct's principal cells through the epithelial Na channel (ENaC) located on the apical side of the cells. Polyuria, renal tubular acidosis and chronic renal failure are the most frequent adverse effects of lithium after 10-20 years of treatment and these alterations can reach to a vasopressin nonresponding form of diabetes insipidus entity called nephrogenic diabetes insipidus. It is believed that the molecular mechanisms of these renal changes are related to a reduction in the number of aquaporin-2 inserted in the apical membrane of the cells. The causes of this are complex. Lithium is a powerful inhibitor of the enzyme glycogen synthase kinase 3ß and this is associated with a lower activity of adenylate cyclase with a reduction in the cAMP levels inside of the cells. The latter may interfere with the synthesis of aquaporin-2 and also with the traffic of these molecules from the subapical site to membrane promoting the impairment of water reabsorption in the distal part of the kidney.


Subject(s)
Antimanic Agents/therapeutic use , Aquaporin 2/physiology , Epithelial Sodium Channels/physiology , Lithium Compounds/therapeutic use , Animals , Antimanic Agents/adverse effects , Antimanic Agents/metabolism , Bipolar Disorder/drug therapy , Diabetes Insipidus, Nephrogenic/chemically induced , Kidney/drug effects , Kidney/metabolism , Kidney Diseases/physiopathology , Lithium/adverse effects , Lithium/metabolism , Lithium/pharmacology , Lithium Compounds/adverse effects , Lithium Compounds/metabolism
7.
Mol Neurobiol ; 59(3): 1706-1723, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35018576

ABSTRACT

Oestrogen deprivation as a consequence of menopause alters the brain neuronal circuit and results in the development of neurobehavioural symptoms later. Hormone replacement therapy to some extent helps to overcome these abnormalities but is associated with various adverse events. Lithium therapy is being used to manage multiple neuropsychiatric disorders and is reported to maintain structural synaptic plasticity, suppress neuroinflammation, and promote adult neurogenesis. The present study examined the effect of lithium treatment on the neurobehavioural impairments in ovariectomized rat model mimicking clinical postmenopausal condition. A protective effect of lithium treatment was observed on the reconsolidation of spatial and recognition memory along with depression-like behaviour in ovariectomized rats. The Golgi-Cox staining revealed increased dendritic length and spine density in the pyramidal neurons of the CA1 region of the hippocampus, layer V of the somatosensory cortex, and layer II/III of the prefrontal cortex in the treated group. A significant reduction in pro-inflammatory markers, Il2, II6, and Il1b, was observed in the hippocampus, somatosensory cortex, and prefrontal cortex following lithium treatment. mRNA expression studies of Gfap and Pparg, along with histopathological analysis, suggested reactive astrogliosis to be a major contributor of neuroinflammation in ovariectomized rats that was normalized following lithium treatment. Further, the treatment inhibited Gsk-3ß activity and maintained the normal level of ß-catenin, CREB, and BDNF. The results revealed a defensive role of lithium against ovariectomy-induced neurobehavioural impairments, thus suggesting it to be a potential therapeutic agent for managing postmenopausal neurological symptoms.


Subject(s)
Hippocampus , Neuroinflammatory Diseases , Animals , Female , Glycogen Synthase Kinase 3 beta/metabolism , Hippocampus/metabolism , Lithium Compounds/metabolism , Lithium Compounds/pharmacology , Pyramidal Cells/metabolism , Rats
8.
Zh Obshch Biol ; 71(4): 359-68, 2010.
Article in Russian | MEDLINE | ID: mdl-20865934

ABSTRACT

The data from scientific publications on excretory activity of herbs root endings were analyzed, along with the data on the role of polyvalent metals cations in stabilization of humus substances (HS) of soil organic mineral complex. On the base of the analysis a working hypothesis was proposed considering root endings influence on fractional composition of soil organic components. To detect the changes taking place in soil HS, the chromatographic fractionation method was chosen. The soil aggregates stuck to root endings of germinating barley seed were washed off, and the washouts were used as the samples for the analysis. The soil from the weighed portion was dissolved directly with extenuating concentrations of LiCl and Li2SO4 alkaline solution. The fractionation was carried out in a chromatographic column. Some changes were detected in optical density of chernozem and dark-grey forest soil leached out after 1-2 days of barley seeds germination. Besides, the experiment showed that the content of organic carbon in HS changes as well.


Subject(s)
Germination , Hordeum/growth & development , Plant Roots/growth & development , Seeds/growth & development , Soil/analysis , Carbon/analysis , Carbon/metabolism , Chemical Fractionation , Chromatography , Hordeum/metabolism , Lithium Chloride/analysis , Lithium Chloride/metabolism , Lithium Compounds/metabolism , Plant Roots/metabolism , Seeds/metabolism , Sulfates/metabolism
9.
Semin Perinatol ; 44(3): 151224, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32199600

ABSTRACT

OBJECTIVE: Breastmilk is recommended as the exclusive source of nutrition for infants younger than 6 months due to the numerous health benefits for both infants and mothers. Although many women are prescribed medications during pregnancy and postpartum, limited data are available to assist women in weighing the benefits compared to the risks of peripartum medication use. The goals of this paper are to discuss the importance of breastmilk for the health of both the mother and infant, evaluate the impact of medication use on women's infant feeding choice, describe the transfer of drugs to breastmilk and infants, and provide a framework for clinicians to support evidence-based counseling for women treated for mood disorders. RECOMMENDATIONS: We recommend early pregnancy counseling to discuss the benefits and risks of medications during breastfeeding. The Surgeon General's Call to Action (2011) highlights the short and long-term negative health effects of not providing breastmilk. Integrating recommendations from the pediatric and obstetric teams allows patients to make decisions based on evidence and reach their infant feeding goals. Databases containing summaries of research findings and pharmacologic properties of the drug of interest are an essential resource for clinicians.


Subject(s)
Antidepressive Agents/pharmacokinetics , Antimanic Agents/pharmacokinetics , Bipolar Disorder/drug therapy , Decision Making , Depressive Disorder/drug therapy , Lactation/metabolism , Milk, Human/chemistry , Antidepressive Agents/adverse effects , Antidepressive Agents/metabolism , Antimanic Agents/adverse effects , Antimanic Agents/metabolism , Antipsychotic Agents/adverse effects , Antipsychotic Agents/metabolism , Antipsychotic Agents/pharmacokinetics , Female , Humans , Lamotrigine/adverse effects , Lamotrigine/metabolism , Lamotrigine/pharmacokinetics , Lithium Compounds/adverse effects , Lithium Compounds/metabolism , Lithium Compounds/pharmacokinetics , Patient Participation
10.
Semin Perinatol ; 44(3): 151230, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32151481

ABSTRACT

Optimal dose management of psychotropic drugs during the perinatal period reduces the risk for recurrence of mood episodes in women with Bipolar Disorder. Physiological changes during pregnancy are associated with decreases in the plasma concentrations of the majority of mood stabilizing medications. Regular symptom and drug concentration monitoring for lithium and anticonvulsants with reflexive dose adjustment improves the probability of sustained symptom remission across pregnancy. The elimination clearance trajectory across pregnancy for psychotropics dictates the frequency of laboratory monitoring and dose adjustment. The literature on the pharmacokinetics of lithium, lamotrigine, carbamazepine and atypical antipsychotics during pregnancy and postpartum are reviewed, recommendations for symptom and laboratory monitoring are proposed and recommendations for dose adjustments are presented.


Subject(s)
Antimanic Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Lactation/metabolism , Pregnancy Complications/drug therapy , Pregnancy/metabolism , Puerperal Disorders/drug therapy , Antimanic Agents/metabolism , Antimanic Agents/pharmacokinetics , Antipsychotic Agents/metabolism , Antipsychotic Agents/pharmacokinetics , Carbamazepine/metabolism , Carbamazepine/pharmacokinetics , Carbamazepine/therapeutic use , Drug Elimination Routes , Female , Humans , Lamotrigine/metabolism , Lamotrigine/pharmacokinetics , Lamotrigine/therapeutic use , Lithium Compounds/metabolism , Lithium Compounds/pharmacokinetics , Lithium Compounds/therapeutic use , Perinatal Care , Prenatal Exposure Delayed Effects
11.
J Neuroinflammation ; 6: 9, 2009 Mar 11.
Article in English | MEDLINE | ID: mdl-19284588

ABSTRACT

BACKGROUND: Septic shock is a prevalent condition that, when not lethal, often causes disturbances in cognition, mood, and behavior, particularly due to central actions of the inflammatory cytokine interleukin-6 (IL-6). To identify potential targets to control brain IL-6, we tested if IL-6 produced by glia is regulated by signal transducer and activator of transcription-3 (STAT3) and glycogen synthase kinase-3 (GSK3). METHODS: Lipopolysaccharide (LPS) was used to induce inflammatory responses in mice or cultured primary glia. IL-6 was measured by ELISA and other inflammatory molecules were measured using an array. RESULTS: Mouse brain IL-6 levels increased after central, as well as peripheral, LPS administration, consistent with glia producing a portion of brain IL-6. STAT3 in the brain was activated after peripheral or central LPS administration, and in LPS-stimulated cultured primary glia. Inhibition of STAT3 expression, function, or activation reduced by ~80% IL-6 production by primary glia, demonstrating the dependence on active STAT3. GSK3 promotes STAT3 activation, and array analysis of inflammatory molecules produced by LPS-stimulated primary glia demonstrated that IL-6 was the cytokine most diminished (>90%) by GSK3 inhibition. Inhibition of GSK3, and knockdown of GSK3beta, not GSK3alpha, greatly inhibited IL-6 production by LPS-stimulated primary glia. Conversely, expression of active STAT3 and active GSK3 promoted IL-6 production. In vivo inhibition of GSK3 reduced serum and brain IL-6 levels, brain STAT3 activation, and GFAP upregulation following LPS administration. CONCLUSION: STAT3 and GSK3 cooperatively promote neuroinflammation, providing novel targets for anti-inflammatory intervention.


Subject(s)
Brain/physiology , Glycogen Synthase Kinase 3/metabolism , Interleukin-6/metabolism , Lipopolysaccharides/toxicity , STAT3 Transcription Factor/metabolism , Animals , Brain/drug effects , Cells, Cultured , Cytokines/blood , Cytokines/metabolism , Escherichia coli , Gene Knockdown Techniques , Glial Fibrillary Acidic Protein/metabolism , Glycogen Synthase Kinase 3/antagonists & inhibitors , Inflammation/chemically induced , Interleukin-6/blood , Lithium Compounds/metabolism , Male , Mice , Mice, Inbred C57BL , Neuroglia/drug effects , Neuroglia/physiology , Sepsis/physiopathology
12.
Biochem Soc Trans ; 37(Pt 5): 1133-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19754466

ABSTRACT

Lithium is widely used to treat bipolar disorder, but its mechanism of action in this disorder is unknown. Lithium directly inhibits GSK3 (glycogen synthase kinase 3), a critical regulator of multiple signal transduction pathways. Inhibition of GSK3 provides a compelling explanation for many of the known effects of lithium, including effects on early development and insulin signalling/glycogen synthesis. However, lithium also inhibits inositol monophosphatase, several structurally related phosphomonoesterases, phosphoglucomutase and the scaffolding function of beta-arrestin-2. It is not known which of these targets is responsible for the behavioural or therapeutic effects of lithium in vivo. The present review discusses basic criteria that can be applied to model systems to validate a proposed direct target of lithium. In this context, we describe a set of simple behaviours in mice that are robustly affected by chronic lithium treatment and are similarly affected by structurally diverse GSK3 inhibitors and by removing one copy of the Gsk3b gene. These observations, from several independent laboratories, support a central role for GSK3 in mediating behavioural responses to lithium.


Subject(s)
Antimanic Agents/metabolism , Glycogen Synthase Kinase 3/antagonists & inhibitors , Lithium Compounds/metabolism , Animals , Antimanic Agents/pharmacology , Antimanic Agents/therapeutic use , Behavior, Animal/drug effects , Glycogen Synthase Kinase 3/metabolism , Humans , Lithium Compounds/pharmacology , Lithium Compounds/therapeutic use , Neurons/drug effects , Neurons/metabolism , Neuropsychological Tests , Phosphoric Monoester Hydrolases/metabolism , Reproducibility of Results , Signal Transduction/drug effects
13.
Am J Geriatr Psychiatry ; 17(1): 13-23, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18626002

ABSTRACT

OBJECTIVES: The authors investigated the relationship between brain lithium, serum lithium and age in adult subjects treated with lithium. In addition, the authors investigated the association between brain lithium and serum lithium with frontal lobe functioning and mood in a subgroup of older subjects. DESIGN: Cross-sectional assessment. SETTING: McLean Hospital's Geriatric Psychiatry Research Program and Brain Imaging Center; The Division of Psychiatry, Boston University School of Medicine. PARTICIPANTS: Twenty-six subjects, 20 to 85 years, with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-TR bipolar disorder (BD), currently treated with lithium. MEASUREMENTS: All subjects had measurements of mood (Hamilton Depression Rating Scale [HDRS] and Young Mania Rating Scale) and serum and brain lithium levels. Brain lithium levels were assessed using lithium Magnetic Resonance Spectroscopy. Ten subjects older than 50 years also had assessments of frontal lobe functioning (Stroop, Trails A and B, Wis. Card Sorting Task). RESULTS: Brain lithium levels correlated with serum lithium levels for the group as a whole. However, this relationship was not present for the group of subjects older than 50. For these older subjects elevations in brain (but not serum) lithium levels were associated with frontal lobe dysfunction and higher HDRS scores. The higher HDRS were associated with increased somatic symptoms. CONCLUSION: Frontal lobe dysfunction and elevated depression symptoms correlating with higher brain lithium levels supports conservative dosing recommendations in bipolar older adults. The absence of a predictable relationship between serum and brain lithium makes specific individual predictions about the "ideal" lithium serum level in an older adult with BD difficult.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Lithium Compounds/therapeutic use , Adult , Affect/drug effects , Age of Onset , Aged , Aged, 80 and over , Bipolar Disorder/metabolism , Brain Chemistry , Cognition/drug effects , Female , Frontal Lobe/physiology , Humans , Lithium Compounds/blood , Lithium Compounds/metabolism , Magnetic Resonance Spectroscopy , Male , Middle Aged , Neuropsychological Tests
14.
Naunyn Schmiedebergs Arch Pharmacol ; 392(7): 785-799, 2019 07.
Article in English | MEDLINE | ID: mdl-30790031

ABSTRACT

Regulation of Na+/K+-ATPase in bipolar disorder and lithium therapy has been investigated for more than 40 years. Contradictory results in this area may be caused by the difference between acute and long-term Li effects on cell metabolism and variance in responsiveness of different cell types. We compared the time-course of Li action focusing on Na+/K+-ATPase and lipid peroxidation in two widely different cell models-Jurkat and HEK293. Na+/K+-ATPase expression level was determined in cells cultivated in the absence or presence of 1 mM Li for different time spans (1, 7, and 28 days) using [3H] ouabain binding and immunoblot assay of α-subunit. In parallel samples, the formation of malondialdehyde (MDA) was quantified by HPLC, and 4-hydroxy-2-nonenal (4-HNE) protein adducts were determined by immunoblot. Cultivation of Jurkat cells in 1 mM Li medium resulted in downregulation of Na+/K+-ATPase (decrease of [3H] ouabain-biding sites and intensity of immunoblot signals) in all Li-groups. In HEK293 cells, the decrease of Na+/K+-ATPase was observed after the acute, 1-day exposure only. The long-term treatment with Li resulted in Na+/K+-ATPase upregulation. MDA and 4-HNE modified proteins were decreased in Jurkat cells in all Li-groups. On the other hand, in HEK293 cells, MDA concentration was decreased after the acute, 1-day Li exposure only; the long-term cultivations, for 7 or 28 days, resulted in a significant increase of lipid peroxidation products. The Li-induced decrease of lipid peroxidation products was associated with the decrease of Na+/K+-ATPase level and vice versa.


Subject(s)
Lipid Peroxidation/drug effects , Lipid Peroxides/metabolism , Lithium Compounds/pharmacology , Sodium-Potassium-Exchanging ATPase/metabolism , Bipolar Disorder/drug therapy , Bipolar Disorder/metabolism , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , HEK293 Cells , Humans , Jurkat Cells , Lithium Compounds/administration & dosage , Lithium Compounds/metabolism , Sodium-Potassium-Exchanging ATPase/genetics , Time Factors
15.
Neuropharmacology ; 54(3): 577-87, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18096191

ABSTRACT

In addition to its clinical antimanic effects, lithium also has efficacy in the treatment of depression. However, the mechanism by which lithium exerts its antidepressant effects is unclear. Our objective was to further characterize the effects of peripheral and central administration of lithium in mouse models of antidepressant efficacy as well as to investigate the role of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors in these behaviors. We utilized the mouse forced swim test (FST) and tail suspension test (TST), intracerebroventricular (ICV) lithium administration, AMPA receptor inhibitors, and BS3 crosslinking followed by Western blot. Both short- and long-term administration of lithium resulted in robust antidepressant-like effects in the mouse FST and TST. Using ICV administration of lithium, we show that these effects are due to actions of lithium on the brain, rather than to peripheral effects of the drug. Both ICV and rodent chow (0.4% LiCl) administration paradigms resulted in brain lithium concentrations within the human therapeutic range. The antidepressant-like effects of lithium in the FST and TST were blocked by administration of AMPA receptor inhibitors. Additionally, administration of lithium increased the cell surface expression of GluR1 and GluR2 in the mouse hippocampus. Collectively, these data show that lithium exerts centrally mediated antidepressant-like effects in the mouse FST and TST that require AMPA receptor activation. Lithium may exert its antidepressant effects in humans through AMPA receptors, thus further supporting a role of targeting AMPA receptors as a therapeutic approach for the treatment of depression.


Subject(s)
Antidepressive Agents/administration & dosage , Depression/drug therapy , Hindlimb Suspension/methods , Lithium Compounds/administration & dosage , Receptors, AMPA/physiology , Swimming , Animals , Antidepressive Agents/metabolism , Behavior, Animal/drug effects , Benzodiazepines/pharmacology , Brain/drug effects , Brain/metabolism , Depression/etiology , Disease Models, Animal , Drug Administration Routes , Excitatory Amino Acid Antagonists/pharmacology , Exploratory Behavior/drug effects , Injections, Intraventricular/methods , Lithium Compounds/metabolism , Mice , Mice, Inbred C57BL , Protein Transport/drug effects , Quinoxalines/pharmacology , Time Factors
16.
J Control Release ; 111(3): 362-7, 2006 Apr 10.
Article in English | MEDLINE | ID: mdl-16488047

ABSTRACT

The objective of this work was to demonstrate that the efficiency of iontophoretic transport across the skin (which is measured in terms of an ion's transport number), either for drug delivery or for therapeutic drug monitoring, depends implicitly on the molar fraction of the species of interest over a wide range of experimental conditions both in vitro and in vivo. Three sets of data from the literature were assessed to establish the direct relationship between transport number and mole fraction. Linear regression between these parameters yielded slopes which correlated with the charge-carrying efficiency of the ion considered. The latter, furthermore, was proportional to the corresponding aqueous mobility and to the transport number of the ion when it is the sole species available for migration from its electrode solution (the so-called "single-carrier" situation). Finally, the principles illustrated here were equally applicable to in vitro experiments and to in vivo data obtained in a clinically relevant study (specifically, the reverse iontophoretic monitoring of lithiemia in bipolar patients). Not only does this validate an in vitro model typically used in iontophoresis research, it also demonstrates the potential of this approach to predict the feasibility of iontophoretic transport across the skin.


Subject(s)
Antimanic Agents/metabolism , Iontophoresis/methods , Lithium Compounds/metabolism , Skin Absorption , Antimanic Agents/therapeutic use , Biological Transport , Bipolar Disorder/drug therapy , Bipolar Disorder/metabolism , Cations , Drug Monitoring , Humans , Lithium Compounds/therapeutic use , Reproducibility of Results
17.
Acta Crystallogr Sect F Struct Biol Cryst Commun ; 62(Pt 10): 1049-51, 2006 Oct 01.
Article in English | MEDLINE | ID: mdl-17012810

ABSTRACT

Dihydroorotate dehydrogenases (DHODHs) are flavin-containing enzymes that catalyze the oxidation of L-dihydroorotate to orotate, the fourth step in the de novo pyrimidine nucleotide synthesis pathway. In this study, DHODH from Leishmania major has been crystallized by the vapour-diffusion technique using lithium sulfate as the precipitating agent. The crystals belong to space group P6(1), with unit-cell parameters a = 143.7, c = 69.8 A. X-ray diffraction data were collected to 2.0 A resolution using an in-house rotating-anode generator. Analysis of the solvent content and the self-rotation function indicate the presence of two molecules in the asymmetric unit. The structure has been solved by the molecular-replacement technique.


Subject(s)
Leishmania major/enzymology , Oxidoreductases Acting on CH-CH Group Donors/chemistry , Animals , Crystallization , Dihydroorotate Dehydrogenase , Lithium Compounds/metabolism , Oxidoreductases Acting on CH-CH Group Donors/isolation & purification , Sulfates/metabolism , X-Ray Diffraction
18.
Spectrochim Acta A Mol Biomol Spectrosc ; 65(5): 1234-40, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16822712

ABSTRACT

The polymer electrolytes composed of poly(vinyl acetate) (PVAc) with various stoichiometric ratios of lithium perchlorate (LiClO(4)) salt have been prepared by solution casting method. The techniques Fourier transform infra-red (FTIR) and Laser Raman spectroscopy have been used to monitor polymer-salt complex formation, ion-ion and ion-polymer interactions as a function of salt concentration. Significant changes in both Laser Raman and FTIR spectra are observed which reveals an interaction between ester oxygens with lithium cation coordination. These results strongly suggest the interaction of lithium cation and network polymer chains. When the salt content is increased, the intensity of the internal Raman modes of the ClO(4)(-) increases. The ClO(4)(-) stretching mode observed at 934 cm(-1) in Laser Raman shows some additional shoulder peaks with increase in salt concentration. This reveals the presence of free anions, ion contact pairs and higher order ionic clusters. From the FTIR and Laser Raman results the transport mechanism of ions in PVAc:LiClO(4) polymer electrolytes has been discussed.


Subject(s)
Lithium Compounds/chemistry , Lithium/metabolism , Perchlorates/chemistry , Polyvinyls/chemistry , Spectrum Analysis, Raman/methods , Electrolytes/chemistry , Ion Transport/physiology , Lithium Compounds/metabolism , Perchlorates/metabolism , Polymers/chemistry , Polyvinyls/metabolism , Spectroscopy, Fourier Transform Infrared
19.
Spectrochim Acta A Mol Biomol Spectrosc ; 61(3): 403-11, 2005 Jan 14.
Article in English | MEDLINE | ID: mdl-15582807

ABSTRACT

A molten salt electrolyte composed of lithium triflate (LiCF3SO3) and acetamide (CH3CONH2) has been prepared and characterized by Raman, IR spectroscopy and ac impedance. It is found that acetamide molecule not only complexes with the Li+ cation but also interacts with the CF3SO3- anion via hydrogen bonding due to its two polar groups (C=O group and NH2 group) capable of coordinating with cations and anions, respectively. Cation-anion interaction is strengthened while cation-solvent and anion-solvent interactions are weakened with the increases of salt concentration and temperature in the LiCF3SO3/acetamide complex. The ionic conductivities of the LiCF3SO3/acetamide complex with different molar ratios depend strongly on the ionic association in the complex system.


Subject(s)
Anions/metabolism , Cations/metabolism , Lithium Compounds/metabolism , Solvents/metabolism , Acetamides , Anions/chemistry , Cations/chemistry , Drug Interactions , Hydrogen Bonding , Lithium Compounds/chemistry , Mesylates/chemistry , Solvents/chemistry , Spectrophotometry, Infrared , Spectrum Analysis, Raman
20.
Eur J Cancer ; 34(1): 188-92, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9624256

ABSTRACT

Essential fatty acids, especially gamma linolenic (GLA) and eicosapentaenoic acids, have been proposed as potential anticancer drugs. Our aim was to study the effect of the lithium salt of gamma linolenic acid (LiGLA) on the growth of two human pancreatic cancer cell lines (MIA PaCa2 and Panc 1) and primary human fibroblasts (HFF 5) in vitro. Cell growth was assessed by a microculture tetrazolium (MTT) assay. LiGLA had a selective growth inhibitory effect on pancreatic cancer cell lines with 50% growth inhibition (IC50) at approximately 6-16 mumol/l compared with approximately 111 mumol/l for the fibroblasts. The degree of growth inhibition increased with the time of exposure to LiGLA. Special attention was paid to the influence of albumin and iron on LiGLA-mediated growth inhibition. Albumin incorporated into essentially serum-free culture medium inhibited the effect of LiGLA in a dose-dependent manner, associated with reduced GLA uptake by cancer cells. Ferric ions were confirmed as potentiators of the growth inhibitory effect of LiGLA but more physiologically relevant transferrin-bound iron was ineffective. With further improvements in the fatty acid delivery mechanism, LiGLA may become a useful adjunct in the management of pancreatic cancer patients.


Subject(s)
Albumins/pharmacology , Ferric Compounds/pharmacology , Pancreatic Neoplasms/drug therapy , gamma-Linolenic Acid/therapeutic use , Cell Division/drug effects , Chlorides , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Lithium Compounds/metabolism , Lithium Compounds/therapeutic use , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Tumor Cells, Cultured/drug effects , gamma-Linolenic Acid/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL